Expect More With TUKYSA
Here’s what you can expect with TUKYSA:
Select Safety Information
What should I tell my healthcare provider before taking TUKYSA?
Before taking TUKYSA, tell your healthcare provider about all of your medical conditions, including if you:
- have liver problems.
- are pregnant or plan to get pregnant. TUKYSA can harm your unborn baby.
Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start taking TUKYSA. Use effective birth control (contraception) during TUKYSA treatment and for at least 1 week after the last dose of TUKYSA. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TUKYSA.
Males with a female partner who can get pregnant: Use effective birth control during TUKYSA treatment and for at least 1 week after the last dose of TUKYSA.
- are breastfeeding (nursing) or plan to breastfeed. Do not breastfeed during treatment with TUKYSA and for at least 1 week after the last dose of TUKYSA.
Here’s How You’ll Take TUKYSA
TUKYSA is part of a treatment plan that includes trastuzumab and capecitabine.
- TUKYSA is taken orally, twice-a-day
- The recommended dose of TUKYSA is 300 mg twice daily, taken 12 hours apart with or without food
- Swallow tablets whole. Do not chew, crush, or split the tablets. Do not take TUKYSA tablets if they are broken, cracked, or damaged
- If you vomit or miss a dose of TUKYSA, take your next dose at your regular time
- Your doctor may change your dose of TUKYSA if needed
- Receive trastuzumab at your healthcare provider’s office or infusion center on Day 1 and again every 21 days
- Take within 30 minutes after a meal
- TUKYSA and capecitabine can be taken at the same time
- Take capecitabine for 14 days, with a 7-day break before starting again
Remember, even though you'll stop capecitabine for the last 7 days of the schedule, TUKYSA should be taken every day.
Side Effects are Possible
As with all cancer treatments, side effects are possible. Nearly everyone in the clinical study experienced some side effects, whether they were treated with TUKYSA, along with trastuzumab and capecitabine, or trastuzumab and capecitabine alone.